PTC Therapeutics (PTCT) Expected to Announce Quarterly Earnings on Tuesday

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) is expected to be announcing its Q1 2025 earnings results after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.85 per share and revenue of $437.16 million for the quarter.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT remained flat at $48.19 during midday trading on Tuesday. The stock had a trading volume of 961,803 shares, compared to its average volume of 811,778. PTC Therapeutics has a 1 year low of $24.00 and a 1 year high of $58.38. The company has a market capitalization of $3.80 billion, a P/E ratio of -8.11 and a beta of 0.58. The stock's 50 day moving average price is $50.15 and its 200 day moving average price is $46.33.

Insider Buying and Selling at PTC Therapeutics

In related news, CFO Pierre Gravier sold 1,168 shares of PTC Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $58,516.80. Following the transaction, the chief financial officer now owns 75,603 shares in the company, valued at approximately $3,787,710.30. The trade was a 1.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Christine Marie Utter sold 879 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $44,037.90. Following the completion of the sale, the chief accounting officer now owns 63,442 shares of the company's stock, valued at $3,178,444.20. The trade was a 1.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,501 shares of company stock valued at $1,546,088 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $70.00 price target (up previously from $67.00) on shares of PTC Therapeutics in a report on Friday, March 7th. Royal Bank of Canada restated an "outperform" rating and issued a $65.00 target price on shares of PTC Therapeutics in a report on Tuesday. StockNews.com lowered shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Citigroup raised their price target on PTC Therapeutics from $32.00 to $45.00 and gave the stock a "sell" rating in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. reduced their price objective on PTC Therapeutics from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Two analysts have rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $63.92.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.